Deoxyshikonin: a promising lead drug grass against drug resistance or sensitivity to Helicobacter pylori in an acidic environment
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00959-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Jia-Yin Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Technology Innovation Cooperation Base of Prevention and Control Pathogenic Microbes with Drug Resistance, Youjiang Medical University for Na…. Hauptthemen laut MEDLINE: Helicobacter pylori, Microbial Sensitivity Tests, Anti-Bacterial Agents, Helicobacter Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Helicobacter pylori ( H. pylori ) is closely associated with the diseases such as gastric sinusitis, peptic ulcers, and gastric adenocarcinoma. Its drug resistance is very severe, and new antibiotics are urgently needed. Nine comfrey compounds were screened by antimicrobial susceptibility testing, among which deoxyshikonin had the best inhibitory effect, with a minimum inhibitory concentration (MIC) of 0.5–1 µg/mL. In addition, deoxyshikonin also has a good antibacterial effect in an acidic environment, it is highly safe, and H. pylori does not readily develop drug resistance. Through in vivo experiments, it was proven that deoxyshikonin (7 mg/kg) had a beneficial therapeutic effect on acute gastritis in mice infected with the multidrug-resistant H. pylori BS001 strain. After treatment with desoxyshikonin, colonization of H. pylori in the gastric mucosa of mice was significantly reduced, gastric mucosal damage was repaired, inflammatory factors were reduced, and the treatment effect was better than that of standard triple therapy. Therefore, deoxyshikonin is a promising lead drug to solve the difficulty of drug resistance in H. pylori , and its antibacterial mechanism may be to destroy the biofilm and cause an oxidation reaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangxi Technology Innovation Cooperation Base of Prevention and Control Pathogenic Microbes with Drug Resistance, Youjiang Medical University for Nationalities, Baise, China.
- Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
- Guangxi Zhuang Autonomous Region Engineering Research Center of Clinical Prevention and Control Technology and Leading Drug for Microorganisms with Drug Resistance in Border Ethnic Areas, Baise, China.
- Department of Pathology, School of Basic Medical Sciences, Wannan Medical College, Wuhu, China.
- Department of Gastroenterology, Wujin People's Hospital affiliated to JiangSu University, Changzhou, China.
- Guangxi Clinical Medical Research Center for Hepatobiliary Diseases, Liuzhou, China.
ORCID-Profile: Liang Huang, Ai-Xing Guan, Yan-Qiang Huang
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
Zitieren
APA
Xu, J., Dong, H., Liao, L., Yang, S., Wang, L., Chen, H., Luo, P., Huang, L., Guan, A., & Huang, Y. Q. (2024). Deoxyshikonin: a promising lead drug grass against drug resistance or sensitivity to Helicobacter pylori in an acidic environment. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00959-24
Vancouver
Xu J, Dong H, Liao L, Yang S, Wang L, Chen H, et al. Deoxyshikonin: a promising lead drug grass against drug resistance or sensitivity to Helicobacter pylori in an acidic environment. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00959-24
BibTeX
@article{Xu2024,
author = {Xu, Jia-Yin and Dong, Hui-Hua and Liao, Li-Juan and Yang, Shi-Xian and Wang, Lu-Yao and Chen, Hao and Luo, Peipei and Huang, Liang and Guan, Ai-Xing and Huang, Yan-Qiang},
title = {Deoxyshikonin: a promising lead drug grass against drug resistance or sensitivity to Helicobacter pylori in an acidic environment},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00959-24}
}
EUVIMED